Modality
Peptide
MOA
PCSK9i
Target
DLL3
Pathway
Complement
CRC
Development Pipeline
Preclinical
Mar 2020
→ Feb 2027
PreclinicalCurrent
NCT08925702
2,217 pts·CRC
2020-03→2027-02·Completed
2,217 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-2711mo awayInterim· CRC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Complet…
Catalysts
Interim
2027-02-27 · 11mo away
CRC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08925702 | Preclinical | CRC | Completed | 2217 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR |